Oncologic outcomes of total length Gleason pattern 4 on biopsy in men with grade group 2 prostate cancer Journal Article


Authors: Perera, M.; Assel, M. J.; Benfante, N. E.; Vickers, A. J.; Reuter, V. E.; Carlsson, S.; Laudone, V.; Touijer, K. A.; Eastham, J. A.; Scardino, P. T.; Fine, S. W.; Ehdaie, B.
Article Title: Oncologic outcomes of total length Gleason pattern 4 on biopsy in men with grade group 2 prostate cancer
Abstract: Purpose:Gleason Score 7 prostate cancer comprises a wide spectrum of disease risk, and precise substratification is paramount. Our group previously demonstrated that the total length of Gleason pattern (GP) 4 is a better predictor than %GP4 for adverse pathological outcomes at radical prostatectomy. We aimed to determine the association of GP4 length on prostate biopsy with post-prostatectomy oncologic outcomes.Materials and Methods:We compared 4 GP4 quantification methods - including maximum %GP4 in any single core, overall %GP4, total length GP4 (mm) across all cores and length GP4 (mm) in the highest volume core - for prediction of biochemical recurrence-free survival after radical prostatectomy using multivariable Cox proportional hazards regression.Results:A total of 457 men with grade group 2 prostate cancer on biopsy subsequently underwent radical prostatectomy. The 3-year biochemical recurrence-free survival probability was 85% (95% CI 81-88). On multivariable analysis, all 4 GP4 quantification methods were associated with biochemical recurrence - maximum %GP4 (HR=1.30; 95% CI 1.07-1.59; p=0.009), overall %GP4 (HR=1.61; 95% CI 1.21-2.15; p=0.001), total length GP4 (HR=2.48; 95% CI 1.36-4.52; p=0.003) and length GP4 in highest core (HR=1.32; 95% CI 1.11-1.57; p=0.001). However, we were unable to identify differences between methods of quantification with a relatively low event rate.Conclusions:These findings support further studies on GP4 quantification in addition to the ratio of GP3 and GP4 to classify prostate cancer risk. Research should also be conducted on whether GP4 quantification could provide a surrogate endpoint for disease progression for trials in active surveillance. © 2022 Lippincott Williams and Wilkins. All rights reserved.
Keywords: cancer grading; biomarkers; prostate specific antigen; neoplasm recurrence, local; pathology; biopsy; prostate-specific antigen; prostatic neoplasms; prostate; prostatectomy; tumor recurrence; prostate tumor; surgery; neoplasm grading; humans; human; male
Journal Title: Journal of Urology
Volume: 208
Issue: 2
ISSN: 0022-5347
Publisher: Elsevier Science, Inc.  
Date Published: 2022-08-01
Start Page: 309
End Page: 316
Language: English
DOI: 10.1097/ju.0000000000002685
PUBMED: 35363038
PROVIDER: scopus
PMCID: PMC9283280
DOI/URL:
Notes: Article -- Export Date: 1 August 2022 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Vincent Laudone
    136 Laudone
  2. Peter T Scardino
    671 Scardino
  3. Karim Abdelkrim Touijer
    257 Touijer
  4. Andrew J Vickers
    880 Vickers
  5. Behfar Ehdaie
    173 Ehdaie
  6. James Eastham
    537 Eastham
  7. Samson W Fine
    457 Fine
  8. Victor Reuter
    1223 Reuter
  9. Sigrid Viktoria Carlsson
    220 Carlsson
  10. Melissa Jean Assel
    110 Assel
  11. Nicole E Benfante
    160 Benfante
  12. Marlon Lakmal Perera
    24 Perera